Clinically important interaction between tedisamil and verapamil

Journal of Clinical Pharmacology

Volumn 49, Issue 5, 2009, Pages 560-567

  Van Haarst, Aernout D ^a   Dijkmans, Anneke C ^a   Weimann, Hans Josef ^b   Kemme, Michiel J B ^a   Bosch, Jacobus J ^a   Schoemaker, Rik C ^a   Cohen, Adam F ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Heart rate; PR; QT; QTc; Tedisamil; Verapamil

Indexed keywords

NORVERAPAMIL; PLACEBO; TEDISAMIL; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART OUTPUT; HEART RATE; HUMAN; MALE; MONOTHERAPY; NORMAL HUMAN; PR INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T WAVE INVERSION;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PRESSURE; CROSS-OVER STUDIES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; VERAPAMIL;

EID: 65449160898     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009332812     Document Type: Article

References (17)

1. Dukes ID, Cleemann L., Morad M. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther. 1990 ; 254: 560-569. (Pubitemid 20262096)
2. Dukes ID, Morad M. The mode of action of tedisamil on voltage dependent K+ channels. Cardiovasc Drugs Ther. 1992 ; 6: 321-327.
3. Bargheer K., Bode F., Klein HU, et al. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J. 1994 ; 15: 1409-1414. (Pubitemid 24326065)
4. Demolis JL, Martel C., Funck-Brentano C., et al. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol. 1997 ; 44: 403-409. (Pubitemid 27402117)
5. Mitrovic V., Oehm E., Thormann J., Pitschner H., Haberbosch W. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease. Clin Cardiol. 1998 ; 21: 492-502. (Pubitemid 28317659)
6. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001 ; 31: 469-497. (Pubitemid 32826389)
7. Leveque D., Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res. 1995 ; 15: 331-336.
8. Mitrovic V., Miskovic A., Strau M., et al. Hemodynamic, antiischemic, and neurohumoral effects of tedisamil and atenolol in patients with coronary artery disease. Cardiovasc Drugs Ther. 2000 ; 14: 511-521.
9. Hermann HP, Ohler A., Just H., Hasenfuss G. Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy. J Cardiovasc Pharmacol. 1998 ; 32: 969-974. (Pubitemid 28563920)
10. Fox KM, Henderson JR, Kaski JC, et al. Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart. 2000 ; 83: 167-171. (Pubitemid 30305543)
11. Freestone B., Lip GY Tedisamil: a new novel antiarrhythmic. Expert Opin Investig Drugs. 2004 ; 13: 151-160. (Pubitemid 38240030)
12. Flores NA Tedisamil (Solvay). Curr Opin Investig Drugs. 2001 ; 2: 97-103. (Pubitemid 32094010)
13. Hohnloser SH, Dorian P., Straub M., Beckmann K., Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol. 2004 ; 44: 99-104. (Pubitemid 38968466)
14. Sagie A., Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992 ; 70: 797-801.
15. Sherwood A., Allen MT, Fahrenberg J., et al. Methodological guidelines for impedance cardiography. Psychophysiology. 1990 ; 27: 1-23. (Pubitemid 20169855)
16. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003 ; 42: 59-98. (Pubitemid 36092258)
17. Pauli M., von R., Burk O., et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 ; 293: 376-382. (Pubitemid 30244084)